Back to Results

Nyxoah (NYXH)

Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea (OSA). Its principal product is the Genio system, a CE-marked, minimally invasive hypoglossal neurostimulation therapy designed for adults with moderate to severe OSA. Incorporated in 2009, Nyxoah is headquartered in Mont-Saint-Guibert, Belgium. The company’s common stock is listed on the NASDAQ under the symbol NYXH.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-NYXH
$2.09
35.1% Upside
Undervalued
$8.37
440.2% Upside
Bargain
Weak
—
—
—
0.0%
August 5, 2026
-1.6x
3.8x
8.9x
156.8 M
170 M
20.8%
68.1%
-12.7
—
87.7%
Valuation • Fair Value

Nyxoah (NASDAQ-NYXH) Fair Value by Valuation Model

Compare the primary fair value estimate for Nyxoah (NASDAQ-NYXH) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$2.09

Estimated upside of 35.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.92

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$1.96

Comparable-company valuation reference.

Analyst Price Target

$8.37

Analysts imply upside of 440.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Nyxoah (NASDAQ-NYXH) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Nyxoah (NASDAQ-NYXH)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

17.716 M

Current operating scale indicator.

Revenue Forecast

42.682 M

Forward revenue estimate.

EBITDA

-94.825 M

Current operating profitability reference.

EBITDA Forecast

-80.868 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Nyxoah (NASDAQ-NYXH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nyxoah (NASDAQ-NYXH)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

-1.31

Higher caution zone on this screen.

Altman Z-Score

-12.7

Lower score that deserves closer risk review.

FCF / Net Income

87.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nyxoah (NASDAQ-NYXH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nyxoah (NASDAQ-NYXH)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Nyxoah (NASDAQ-NYXH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Nyxoah (NASDAQ-NYXH) Stock Forecast & Technical Outlook

Review Nyxoah (NASDAQ-NYXH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Nyxoah (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Nyxoah (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Nyxoah (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Nyxoah (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nyxoah (NASDAQ-NYXH) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nyxoah (NASDAQ-NYXH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Nyxoah (NASDAQ-NYXH) has a Buy consensus, with 2 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 2
Sell 0
FAQ • Fast Investor Answers

Nyxoah (NASDAQ-NYXH) Stock FAQ

Quick answers about Nyxoah (NASDAQ-NYXH) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$2.09
Estimated upside 35.1%
Valuation Rating
Undervalued
Estimated upside of 35.1%
Analyst Target
$8.37
Implied upside 440.2%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Nyxoah (NASDAQ-NYXH) is $2.09. This implies an estimated upside of 35.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 35.1% versus the current market price.

The available analyst price target for Nyxoah (NASDAQ-NYXH) is $8.37. The analyst target implies estimated upside of 440.2%.

The current financial health read for Nyxoah (NASDAQ-NYXH) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nyxoah (NASDAQ-NYXH) is August 5, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Nyxoah (NASDAQ-NYXH) is -1.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Nyxoah is 156.8 M.

The current enterprise value listed for Nyxoah is 170 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nyxoah is NASDAQ-NYXH, and the stock is listed on NASDAQ.

Nyxoah (NASDAQ-NYXH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Nyxoah is 20.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nyxoah is 68.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NASDAQ View more

Intuitive Surgical Inc (ISRG) Intuitive Surgical Inc (ISRG)
Medline Inc (MDLN) Medline Inc (MDLN)
IDEXX Laboratories Inc (IDXX) IDEXX Laboratories Inc (IDXX)
DexCom Inc (DXCM) DexCom Inc (DXCM)
GE HealthCare Technologies Inc (GEHC) GE HealthCare Technologies Inc (GEHC)
Cooper Companies Inc (COO) Cooper Companies Inc (COO)
Align Technology Inc (ALGN) Align Technology Inc (ALGN)
Insulet Corporation (PODD) Insulet Corporation (PODD)
Lantheus Holdings Inc (LNTH) Lantheus Holdings Inc (LNTH)
MiniMed Group Inc (MMED) MiniMed Group Inc (MMED)
Merit Medical Systems Inc (MMSI) Merit Medical Systems Inc (MMSI)
LivaNova PLC (LIVN) LivaNova PLC (LIVN)
ICU Medical Inc (ICUI) ICU Medical Inc (ICUI)
IRhythm Technologies Inc (IRTC) IRhythm Technologies Inc (IRTC)
Establishment Labs Holdings Inc (ESTA) Establishment Labs Holdings Inc (ESTA)
Dentsply Sirona Inc (XRAY) Dentsply Sirona Inc (XRAY)
TransMedics Group Inc (TMDX) TransMedics Group Inc (TMDX)
LeMaitre Vascular Inc (LMAT) LeMaitre Vascular Inc (LMAT)
Neogen Corporation (NEOG) Neogen Corporation (NEOG)
Axogen Inc (AXGN) Axogen Inc (AXGN)
Omnicell Inc (OMCL) Omnicell Inc (OMCL)
Pulse Biosciences Inc (PLSE) Pulse Biosciences Inc (PLSE)
UFP Technologies Inc (UFPT) UFP Technologies Inc (UFPT)
Novocure Ltd (NVCR) Novocure Ltd (NVCR)